An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants

NCT00591565 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Anxiety

Interventions

DRUG: Acamprosate

Sponsor

State University of New York - Upstate Medical University

Collaborators

[object Object]